Jiangsu Huifeng Bio Agriculture Co (002496) Fair Value & Analysis
Basic Materials · CN · Market cap 3.6B CNY
Analysis
Jiangsu Huifeng Bio Agriculture Co (002496) currently trades at ¥2.17, while our model-based Fair Value estimate is ¥2.22 — implying the stock looks roughly 2.3% undervalued today. We read business quality at 93/100 (high quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
Jiangsu Huifeng Bio Agriculture Co., Ltd. engages in the research, development, production, and sale of pesticide preparations in the People's Republic of China and internationally. The company offers Nengbaiwang, Shengshi Nianjing series of biological pesticides, Huifeng Gaogui, Nengjianyuan, Shengshigenyuan system water-soluble fertilizers, and selenium-enriched functional products, etc. It also offers biostimulants; brand operation, agricultural materials e-commerce, and petrochemical supply chain, etc.; and technical, formulation, and fine chemicals products. The company serves pesticides, fertilizers, seeds, pharmaceutical intermediates, petrochemical warehousing, and fine chemicals industries. The company was formerly known as Jiangsu Huifeng Agrochemical Co., Ltd. and changed its name to Jiangsu Huifeng Bio Agriculture Co., Ltd. in August 2017. Jiangsu Huifeng Bio Agriculture Co., Ltd. was founded in 1999 and is headquartered in Yancheng, the People's Republic of China.
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.